A Phase 4 interventional study of Ibrutinib 420 mg and Ibrutinib 560 mg in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Mantle-Cell, sponsored by Johnson & Johnson Private Limited. Completed at 10 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 29th largest by enrollment, is one of 7 that started in 2019, is the only one in phase 4, and was the 52nd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Private Limited, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Private Limited is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson: 3 open now, 7 under way, 2 of them phase 3. Of 16 finished, 3 (19%) have results posted.
Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 4, and was the 11th registered.
Johnson & Johnson’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1990.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Johnson & Johnson’s 26 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
Drug: Ibrutinib 420 mg · Drug: Ibrutinib 560 mg
Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
Also known as: Imbruvica
Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
Also known as: Imbruvica
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.
Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE which resulted in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.
Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)
| Milestone | Ibrutinib |
|---|---|
| Started | 75 |
| Participants with cll | 67 |
| Participants with mcl | 8 |
| Completed | 55 |
| Not completed | 20 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 10 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Progressive disease | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.
| Participants | Ibrutinib |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 62 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE which resulted in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study drug up to maximum of 30 days after last dose was considered as treatment emergent.
| Participants | Ibrutinib |
|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) | 23 |
Collected over Day 1 up to 30 days after last dose of study drug (up to 13 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib | 10/75 (13.3%) | 23/75 (30.7%) | 55/75 (73.3%) |
| Event | Ibrutinib |
|---|---|
| PyrexiaGeneral disorders | 4/75 |
| Covid-19Infections and infestations | 3/75 |
| Cardio-Respiratory ArrestCardiac disorders | 2/75 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/75 |
| PancytopeniaBlood and lymphatic system disorders | 1/75 |
| Acute Coronary SyndromeCardiac disorders | 1/75 |
| Abdominal PainGastrointestinal disorders | 1/75 |
| DeathGeneral disorders | 1/75 |
| Disease ProgressionGeneral disorders | 1/75 |
| Non-Cardiac Chest PainGeneral disorders | 1/75 |
| Event | Ibrutinib |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/75 |
| VomitingGastrointestinal disorders | 8/75 |
| PyrexiaGeneral disorders | 8/75 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/75 |
| FatigueGeneral disorders | 7/75 |
| HeadacheNervous system disorders | 7/75 |
| DiarrhoeaGastrointestinal disorders | 6/75 |
| Decreased AppetiteMetabolism and nutrition disorders | 6/75 |
| FuruncleInfections and infestations | 5/75 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/75 |
| Age, Continuous(years) | Ibrutinib |
|---|---|
| Mean | 61.9 ± 11.81 |
| Sex: Female, Male(Participants) | Ibrutinib |
|---|---|
| Female | 23 |
| Male | 52 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 75 |
| Race (NIH/OMB)(Participants) | Ibrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 75 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Ibrutinib |
|---|---|
| India | 75 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in May 2023, 46 months.
Results were first posted in May 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →
Johnson & Johnson Private Limited →